In daily practice, neurosurgeons face increasing numbers of patients using aspirin (acetylsalicylic acid, ASA). While many of these patients discontinue ASA 7–10 days prior to elective intracranial surgery, there are limited data to support whether or not perioperative ASA use heightens the risk of hemorrhagic complications. In this study the authors retrospectively evaluated the safety of perioperative ASA use in patients undergoing craniotomy for brain tumors in the largest elective cranial surgery cohort reported to date.
The authors retrospectively analyzed the medical records of 1291 patients who underwent elective intracranial tumor surgery by a single surgeon from 2007 to 2017. The patients were divided into three groups based on their perioperative ASA status: 1) group 1, no ASA; 2) group 2, stopped ASA (low cardiovascular risk); and 3) group 3, continued ASA (high cardiovascular risk). Data collected included demographic information, perioperative ASA status, tumor characteristics, extent of resection (EOR), operative blood loss, any hemorrhagic and thromboembolic complications, and any other complications.
A total of 1291 patients underwent 1346 operations. The no-ASA group included 1068 patients (1112 operations), the stopped-ASA group had 104 patients (108 operations), and the continued-ASA group had 119 patients (126 operations). The no-ASA patients were significantly younger (mean age 53.3 years) than those in the stopped- and continued-ASA groups (mean 64.8 and 64.0 years, respectively; p < 0.001). Sex distribution was similar across all groups (p = 0.272). Tumor locations and pathologies were also similar across the groups, except for deep tumors and schwannomas that were relatively less frequent in the continued-ASA group. There were no differences in the EOR between groups. Operative blood loss was not significantly different between the stopped- (186 ml) and continued- (220 ml) ASA groups (p = 0.183). Most importantly, neither hemorrhagic (0.6%, 0.9%, and 0.8%, respectively; p = 0.921) nor thromboembolic (1.3%, 1.9%, and 0.8%; p = 0.779) complication rates were significantly different between the groups, respectively. In addition, the multivariate model revealed no statistically significant predictor of hemorrhagic complications, whereas male sex (odds ratio [OR] 5.9, 95% confidence interval [CI] 1.7–20.5, p = 0.005) and deep-extraaxial-benign (“skull base”) tumors (OR 3.6, 95% CI 1.3–9.7, p = 0.011) were found to be independent predictors of thromboembolic complications.
In this cohort, perioperative ASA use was not associated with the increased rate of hemorrhagic complications following intracranial tumor surgery. In patients at high cardiovascular risk, ASA can safely be continued during elective brain tumor surgery to prevent potential life-threatening thromboembolic complications. Randomized clinical trials with larger sample sizes are warranted to achieve a greater statistical power.
ABBREVIATIONSASA = acetylsalicylic acid; CI = confidence interval; EOR = extent of resection; MI = myocardial infarction; OR = odds ratio.
Akhavan-SigariRRohdeVAbiliM: Continuation of medically necessary platelet aggregation inhibitors—acetylsalicylic acid and clopidogrel—during surgery for spinal degenerative disorders: results in 100 patients. Surg Neurol Int5 (Suppl 7):S376–S3792014
BaigentCBlackwellLCollinsREmbersonJGodwinJPetoR: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet373:1849–18602009
BruderMWonSYWagnerMBrawanskiNDincNKashefiolaslS: Continuous acetylsalicylic acid treatment does not influence bleeding pattern or outcome of aneurysmal subarachnoid hemorrhage: a matched-pair analysis. World Neurosurg113:e122–e1282018
BurgerWChemnitiusJMKneisslGDRückerG: Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med257:399–4142005
Darvish-KazemSDouketisJD: Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. Semin Thromb Hemost38:652–6602012
DasenbrockHHYanSCGrossBAGuttieresDGormleyWBFrerichsKU: The impact of aspirin and anticoagulant usage on outcomes after aneurysmal subarachnoid hemorrhage: a Nationwide Inpatient Sample analysis. J Neurosurg126:537–5472017
FleisherLAFleischmannKEAuerbachADBarnasonSABeckmanJABozkurtB: 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation130:2215–22452014
HanHKohEJChoiHKimBCYangSYChoKT: The effect of preoperative antiplatelet therapy on hemorrhagic complications after decompressive craniectomy in patients with traumatic brain injury. Korean J Neurotrauma12:61–662016
KristensenSDKnuutiJSarasteAAnkerSBøtkerHEHertSD: 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J35:2383–24312014
LeeATGagnidzeAPanSRSookplungPNairBNewmanSF: Preoperative low-dose aspirin exposure and outcomes after emergency neurosurgery for traumatic intracranial hemorrhage in elderly patients. Anesth Analg125:514–5202017
LevyMHeels-AnsdellDHiralalRBhandariMGuyattGYusufS: Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology114:796–8062011
SoniA: Aspirin Use Among the Adult U.S. Noninstitutionalized Population, With and Without Indicators of Heart Disease, 2005. Statistical Brief #179. Rockville, MD: Agency for Healthcare Research and Quality2007
WolffGNavareseEPBrockmeyerMLinYKarathanosAKołodziejczakM: Perioperative aspirin therapy in non-cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol258:59–672018